

Behandeling hyperglycemie

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|-----------------------------|--------------------------|----------------------------|---------------------------------|------------------------------------|--|----|--------------------|--------------------|-------------|-------------|--|----|--------|--------------------|-------------|--|----|--------|--------------------|-------------|---|----|--------|-------------|---|-----|--------------------|--------------------|-------------|
| | Gezond eten, gewichtscontrole, verhoogde fysieke activiteit en diabeteseducatie | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Monotherapie | Metformine | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Effectiviteit (daling HbA1c) | hoog | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Hypoglycemie | laag risico | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Gewicht | neutraal / gewichtsverlies | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Bijwerkingen | gastro-intestinaal / lactaatacidose | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Kostprijs | laag | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Combinatie van twee geneesmiddelen | <i>Indien de geïndividualiseerde HbA1c-doelstelling na zowat 3 maanden niet werd bereikt, stap dan over op een combinatie van 2 geneesmiddelen. De volgorde zoals hieronder vermeld, geeft geen specifieke voorkeur aan; behandel volgens individueel profiel.</i> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Metformine + | Metformine + | Metformine + | Metformine + | Metformine + | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | sulfonylurea | thiazolidinedione | DPP-4-inhibitor | SGLT2-inhibitor | GLP-1-receptor-agonist | insuline (meestal basaal) | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Effectiviteit (daling HbA1c) | hoog | hoog | gemiddeld | gemiddeld | hoog | hoogst | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Hypoglycemie | gemiddeld | laag risico | laag risico | laag risico | laag risico | hoog risico | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Gewicht | toename | toename | neutraal | verlies | verlies | toename | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Bijwerkingen | hypoglycemie | oedeem, hartfalen, fractuur | zelden | genito-urinair, dehydratie | gastro-intestinaal | hypoglycemie | | | | | | | | | | | | | | | | | | | | | | | | | |
| Kostprijs | laag | laag | hoog | hoog | hoog | variabel | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Combinatie van drie geneesmiddelen | <i>Indien de geïndividualiseerde HbA1c-doelstelling na zowat 3 maanden niet werd bereikt, stap dan over op een combinatie van 3 geneesmiddelen. De volgorde zoals hieronder vermeld, geeft geen specifieke voorkeur aan; behandel volgens individueel profiel.</i> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Metformine + | Metformine + | Metformine + | Metformine + | Metformine + | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | sulfonylurea + | thiazolidinedione + | DPP-4-inhibitor + | SGLT2-inhibitor + | GLP-1-receptor-agonist + | insuline (meestal basaal) + | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | <table border="1"> <tr><td>TZD</td></tr> <tr><td>of DPP-4-inhibitor</td></tr> <tr><td>of SGLT2-inhibitor</td></tr> <tr><td>of GLP-1-RA</td></tr> <tr><td>of insuline</td></tr> </table> | TZD | of DPP-4-inhibitor | of SGLT2-inhibitor | of GLP-1-RA | of insuline | <table border="1"> <tr><td>SU</td></tr> <tr><td>of DPP-4-inhibitor</td></tr> <tr><td>of SGLT2-inhibitor</td></tr> <tr><td>of GLP-1-RA</td></tr> <tr><td>of insuline</td></tr> </table> | SU | of DPP-4-inhibitor | of SGLT2-inhibitor | of GLP-1-RA | of insuline | <table border="1"> <tr><td>SU</td></tr> <tr><td>of TZD</td></tr> <tr><td>of SGLT2-inhibitor</td></tr> <tr><td>of insuline</td></tr> </table> | SU | of TZD | of SGLT2-inhibitor | of insuline | <table border="1"> <tr><td>SU</td></tr> <tr><td>of TZD</td></tr> <tr><td>of DPP-4-inhibitor</td></tr> <tr><td>of insuline</td></tr> </table> | SU | of TZD | of DPP-4-inhibitor | of insuline | <table border="1"> <tr><td>SU</td></tr> <tr><td>of TZD</td></tr> <tr><td>of insuline</td></tr> </table> | SU | of TZD | of insuline | <table border="1"> <tr><td>TZD</td></tr> <tr><td>of DPP-4-inhibitor</td></tr> <tr><td>of SGLT2-inhibitor</td></tr> <tr><td>of GLP-1-RA</td></tr> </table> | TZD | of DPP-4-inhibitor | of SGLT2-inhibitor | of GLP-1-RA |
| | TZD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | of DPP-4-inhibitor | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | of SGLT2-inhibitor | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of GLP-1-RA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of insuline | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| SU | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of DPP-4-inhibitor | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of SGLT2-inhibitor | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of GLP-1-RA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of insuline | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| SU | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of TZD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of SGLT2-inhibitor | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of insuline | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| SU | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of TZD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of DPP-4-inhibitor | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of insuline | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| SU | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of TZD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of insuline | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| TZD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of DPP-4-inhibitor | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of SGLT2-inhibitor | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| of GLP-1-RA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | of | of | of | of | of | of | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | of | of | of | of | of | of | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | of | of | of | of | of | of | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | of | of | of | of | of | of | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | of | of | of | of | of | of | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | of | of | of | of | of | of | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Meer complexe insulinestrategie | <i>Als de HbA1c-doelstelling na zowat 3 maanden combinatietherapie niet is bereikt en de patiënt a) een orale combinatie krijgt, vervang dit door injecties; b) GLP-1-RA krijgt, voeg basaal insuline toe; of c) optimaal getitreerde insuline krijgt, voeg GLP-1-RA of maaltijdinsuline toe. Bij refractaire patiënten, overweeg TZD of SGLT2-I toe te voegen.</i> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Metformine + basaal insuline + (maaltijdinsuline of GLP-1-receptoragonist) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

Bron: American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37.